What's new

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 15, Status: Authorised

Feb 9, 2025 - 21:46
 0
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 15, Status: Authorised
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 15, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin...

Next Article

Human medicines European public assessment report (EPAR): Xiliarx, vildagliptin,...

Related Posts

Human medicines European public assessment report (EPAR): Izelvay, avacincaptad pegol, Status: Application withdrawn

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Template for assessment report for the development of European Union herbal monographs and list entries

Template for assessment report for the development of E...

Feb 17, 2025  0

DARWIN EU Advisory Board meeting: 3 May 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 3 May 2024, 13:00 (CEST) to 3 May 2024, 14:30 (CEST)

DARWIN EU Advisory Board meeting: 3 May 2024, Online, E...

Feb 20, 2025  0